Status:
COMPLETED
Protocol for Eslax Intravenous Drug Use Investigation (Study P06082)
Lead Sponsor:
Merck Sharp & Dohme LLC
Conditions:
Anesthesia
Eligibility:
All Genders
Brief Summary
The main purpose of this investigation is to collect safety and efficacy information of Eslax Intravenous 25mg/2.5mL and 50mg/5.0mL (hereinafter referred to as "Eslax") in daily clinical settings.
Detailed Description
Post-marketing surveys are not considered applicable clinical trials and thus the results of this survey will not be posted at its conclusion. The results will be submitted to public health officials ...
Eligibility Criteria
Inclusion
- Patients to whom Eslax has been administered to relax muscles at the time of anesthesia or tracheal intubation.
Exclusion
- Patients with a history of hypersensitivity to Eslax or bromide.
- Patients with myasthenia gravis or myasthenic syndrome.
Key Trial Info
Start Date :
November 1 2007
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 1 2010
Estimated Enrollment :
3969 Patients enrolled
Trial Details
Trial ID
NCT00902070
Start Date
November 1 2007
End Date
October 1 2010
Last Update
October 30 2015
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.